Johnson & Johnson's Tim Schmid Discusses MedTech Industry Growth and JNJ's Position

Johnson & Johnson (JNJ) Executive VP & Worldwide Chairman of MedTech, Tim Schmid, discusses the state of the medical technology industry at the 2025 Wells Fargo Healthcare Conference. Schmid expects sector growth to remain at 5% to 7%, citing the industry's high attractiveness and strong growth prospects. He also mentions J&J MedTech's annual sales of $32 billion and his experience leading the company in various leadership positions across the globe.

Title: Johnson & Johnson MedTech: Tim Schmid Discusses Industry Growth and Innovation at 2025 Wells Fargo Healthcare Conference

September 2, 2025

Johnson & Johnson (JNJ) Executive Vice President and Worldwide Chairman of MedTech, Tim Schmid, shared his insights on the state of the medical technology industry at the 2025 Wells Fargo Healthcare Conference. Schmid, who has been with the company for over three decades, highlighted the industry's robust growth prospects and J&J MedTech's strategic positioning.

Schmid expects the medical technology sector to grow at a rate of 5% to 7% annually, driven by factors such as aging populations, increased healthcare access, and technological advancements. He noted that J&J MedTech's annual sales of $32 billion reflect its market leadership in numerous categories, with a significant presence in high-growth areas like cardiovascular and digital surgery.

Innovation was a key focus of Schmid's discussion. He emphasized that the industry is on the cusp of an "explosion of innovation," citing advancements in AI, robotics, and personalized care. J&J MedTech's substantial R&D investment, totaling approximately $3.7 billion in 2023, underscores the company's commitment to driving innovation. Additionally, the acquisition of Abiomed and Shockwave, which focus on cardiovascular technologies, highlights the company's strategic approach to expanding its portfolio.

The regulatory environment was also touched upon, with Schmid expressing optimism about the FDA's modernization efforts and its commitment to streamlining approval processes. He noted that recent policy changes, such as the update to MDUFA, have been encouraging for the industry.

Regarding the potential impact of the "one big beautiful bill" on procedure volume, Schmid stated that while the bill's provisions could affect Medicaid, J&J MedTech does not anticipate a significant impact on its business due to its limited reliance on Medicaid. He also highlighted the bill's attractive provisions for companies like J&J, such as the ability to expense R&D investments in the U.S.

Schmid's presentation underscored J&J MedTech's strategic focus on innovation, growth, and regulatory compliance, positioning the company to continue its leadership in the medical technology industry.

References:
[1] https://www.nasdaq.com/articles/johnson-johnson-medtech-announces-positive-findings-varipure-substudy-secure
[2] https://seekingalpha.com/article/4819088-johnson-and-johnson-jnj-presents-at-wells-fargo-20th-annual-healthcare-conference-2025